DUOPHARMA Biotech Bhd booked a 1Q25 core profit of RM30.5m, accounting for 37% and 34% of our and Street’s estimate. Results were above expectations due to a notable surge in insulin supply and improvements in public sector sales. Moving forward, Dupharma Biotech’s growth should be underpinned by the government’s higher budget allocations for the Health Ministry (MOH) and sustained consumer demand for pharmaceutical products. Maintain Buy, higher RM1.50 target price (discounted cash flow) from RM1.34, 17% upside. — RHB Investment Bank Bhd (May 16, 2025)
(Calls by analysts tracked by Bloomberg: 5 Buy, 0 Hold, 0 Sell; Consensus target price: RM1.57)
RELATED ARTICLES
CORP BRIEF: BToto, NCT Alliance, Duopharma Biotech and Datasonic
Duopharma first company to get halal certification for oncology product
Duopharma Biotech’s 4Q19 earnings down 16.3%
Sinopharm vaccine now available in Malaysia
Duopharma Biotech bags RM16.6m supply contract with MOH
Duopharma Biotech, KPJ to raise awareness on halal pharmaceuticals
The post Duopharma Biotech retains Buy, with discounted-cash flow based target price of RM1.50 appeared first on The Malaysian Reserve.
